UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 24, 2006
AMYLIN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
| 0-19700 |
| 33-0266089 |
(State or Other Jurisdiction of |
| (Commission File Number) |
| (I.R.S. Employer Identification No.) |
Incorporation) |
|
|
|
|
9360 Towne Centre Drive
San Diego, California 92121
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (858) 552-2200
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CRF 240.13e-4(c))
Item 8.01. Other Events.
On August 24, 2006, Amylin Pharmaceuticals, Inc. issued a press release announcing that in connection with the previously announced redemption of its outstanding 2.25% convertible senior notes due June 30, 2008 issued in June and July 2003, holders of all of the outstanding notes converted their notes into shares of Amylin’s common stock prior to the August 24, 2006 redemption date. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Number |
| Description |
99.1 |
| Press release issued by Amylin on August 24, 2006. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AMYLIN PHARMACEUTICALS, INC. | |||
|
| ||
|
| ||
Dated: August 24, 2006 | By: | /s/ LLOYD A. ROWLAND |
|
|
| Lloyd A. Rowland | |
|
| Vice President, Legal, Secretary and General Counsel | |
3
EXHIBIT INDEX
Number |
| Description |
99.1 |
| Press release issued by Amylin on August 24, 2006. |
4